70 results on '"Kogner, Per"'
Search Results
2. Pharmacological inhibition of BCL-2 with the FDA-approved drug venetoclax impairs longitudinal bone growth.
- Author
-
Velentza, Lilly, Wickström, Malin, Kogner, Per, Ohlsson, Claes, Zaman, Farasat, and Sävendahl, Lars
- Subjects
- *
BONE growth , *VENETOCLAX , *GROWTH plate , *CELL size , *BONE cells , *HYPERTROPHIC scars , *CARTILAGE regeneration - Abstract
Treatment-related skeletal complications are common in childhood cancer patients and survivors. Venetoclax is a BCL-2 inhibitor that has shown efficacy in hematological malignancies in adults and is being investigated in pediatric cancer clinical trials as a promising therapeutic modality. Venetoclax triggers cell death in cancer cells, but whether it exerts similar effects in normal bone cells, is unknown. Chondrogenic ATDC5 cells, E20 fetal rat metatarsal bones, and human growth plate biopsies were treated with different concentrations of venetoclax. Female NMRI nu/nu mice were treated with venetoclax or vehicle for 15 days. Mice were X-rayed at baseline and at the end of the experiment to assess longitudinal bone growth and body weight was monitored throughout the study. Histomorphometric and immunohistochemical analyses were performed to evaluate treatment effects on the growth plate cartilage. Venetoclax decreased the viability of chondrocytes and impaired the growth of ex vivo cultured metatarsals while reducing the height of the resting/proliferative zone and the hypertrophic cell size. When tested in vivo, venetoclax suppressed bone growth and reduced growth plate height. Our experimental data suggest that venetoclax directly targets growth plate chondrocytes suppressing bone growth and we, therefore, encourage careful monitoring of longitudinal bone growth if treating growing children with venetoclax. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Aggressive neuroblastomas have high p110alpha but low p110delta and p55alpha/p50alpha protein levels compared to low stage neuroblastomas.
- Author
-
Fransson, Susanne, Kogner, Per, Martinsson, Tommy, and Ejeskär, Katarina
- Subjects
- *
NEUROBLASTOMA , *PHOSPHOINOSITIDES , *PHOSPHOLIPIDS , *PROTEIN kinases , *NERVOUS system tumors - Abstract
Background: The phosphoinositide 3-kinase (PI3K)/Akt pathway is involved in neuroblastoma development where Akt/PKB activation is associated with poor prognosis. PI3K activity subsequently activates Akt/PKB, and as mutations of PI3K are rare in neuroblastoma and high levels of PI3K subunit p110delta is associated with favorable disease with low p-Akt/PKB, the levels of other PI3K subunits could be important for Akt activation. Methods: Protein levels of Type IA PI3K catalytic and regulatory subunits were investigated together with levels of phosphorylated Akt/PKB and the PI3K negative regulator PTEN in primary neuroblastoma tumors. Relation between clinical markers and protein levels were evaluated through t-tests. Results: We found high levels of p-Akt/PKB correlating to aggressive disease and p-Akt/PKB (T308) showed inverse correlation to PTEN levels. The regulatory isomers p55alpha/p50alpha showed higher levels in favorable neuroblastoma as compared with aggressive neuroblastoma. The PI3K-subunit p110alpha was found mainly in advanced tumors while p110delta showed higher levels in favorable neuroblastoma. Conclusions: Activation of the PI3K/Akt pathway is seen in neuroblastoma tumors, however the contribution of the different PI3K isoforms is unknown. Here we show that p110alpha is preferentially expressed in aggressive neuroblastomas, with high p-Akt/PKB and p110delta is mainly detected in favorable neuroblastomas, with low p-Akt/PKB. This is an important finding as PI3K-specific inhibitors are suggested for enrollment in treatment of neuroblastoma patients. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
4. Quantitative global and gene-specific promoter methylation in relation to biological properties of neuroblastomas.
- Author
-
Kiss, Nimrod B., Kogner, Per, Inge Johnsen, John, Martinsson, Tommy, Larsson, Catharina, and Geli, Geli
- Subjects
- *
CYSTS (Pathology) , *NEUROBLASTOMA , *TUMORS in children , *NERVOUS system tumors , *TUMOR suppressor genes - Abstract
Background: In this study we aimed to quantify tumor suppressor gene (TSG) promoter methylation densities levels in primary neuroblastoma tumors and cell lines. A subset of these TSGs is associated with a CpG island methylator phenotype (CIMP) in other tumor types. Methods: The study panel consisted of 38 primary tumors, 7 established cell lines and 4 healthy references. Promoter methylation was determined by bisulphate Pyrosequencing for 14 TSGs; and LINE-1 repeat element methylation was used as an indicator of global methylation levels. Results: Overall mean TSG Z-scores were significantly increased in cases with adverse outcome, but were unrelated to global LINE-1 methylation. CIMP with hypermethylation of three or more gene promoters was observed in 6/38 tumors and 7/7 cell lines. Hypermethylation of one or more TSG (comprising TSGs BLU, CASP8, DCR2, CDH1, RASSF1A and RASSF2) was evident in 30/38 tumors. By contrast only very low levels of promoter methylation were recorded for APC, DAPK1, NORE1A, P14, P16, TP73, PTEN and RARB. Similar involvements of methylation instability were revealed between cell line models and neuroblastoma tumors. Separate analysis of two proposed CASP8 regulatory regions revealed frequent and significant involvement of CpG sites between exon 4 and 5, but modest involvement of the exon 1 region. Conclusions/significance: The results highlight the involvement of TSG methylation instability in neuroblastoma tumors and cell lines using quantitative methods, support the use of DNA methylation analyses as a prognostic tool for this tumor type, and underscore the relevance of developing demethylating therapies for its treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
5. Neuroblastoma-related inflammation May small doses of aspirin be suitable for small cancer patients?
- Author
-
Carlson, Lena-Maria and Kogner, Per
- Subjects
- *
NEUROBLASTOMA , *INFLAMMATION , *ASPIRIN , *CANCER patients , *THROMBOXANES - Abstract
The daily intake of low-dose aspirin lowers the risk of several cancers among the adults. The continuous administration of low-dose aspirin to TH-MYCN mice (a model of pediatric neuroblastoma) delays tumor outgrowth and decreases tumor-promoting inflammation by inhibiting regulatory cells of the innate immune system as well as immunosuppressive mediators such as transforming growth factor β (TGFβ) and thromboxane A2. These indings pave novel avenues for the clinical management of neuroblastoma. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
6. The loss of DLG2 isoform 7/8, but not isoform 2, is critical in advanced staged neuroblastoma.
- Author
-
Keane, Simon, Martinsson, Tommy, Kogner, Per, and Ejeskär, Katarina
- Subjects
- *
NEUROBLASTOMA , *CELL polarity , *NEURAL crest , *GENE families , *GENE expression , *CELL communication - Abstract
Background: Neuroblastoma is a childhood neural crest tumor showing large clinical and genetic heterogeneity, one form displaying 11q-deletion is very aggressive. It has been shown that 11q-deletion results in decreased expression of DLG2, a gene residing in the deleted region. DLG2 has a number of different isoforms with the main difference is the presence or absence of a L27 domain. The L27 domain containing DLG proteins can form complexes with CASK/MPP and LIN7 protein family members, which will control cell polarity and signaling. Methods: We evaluated the DLG gene family and the LIN7 gene family for their expression in differently INSS staged neuroblastoma from publically available data and primary tumors, we included two distinct DLG1 and DLG2 N-terminal transcript isoforms encoding L27 domains for their expression. Functionality of DLG2 isoforms and of LIN7A were evaluated in the 11q-deleted neuroblastoma cell line SKNAS. Results: In neuroblastoma only two DLG2 isoforms were expressed: isoform 2 and isoform 7/8. Using the array data we could determine that higher expression of DLG members that contain L27 domains correlated to better survival and prognosis. Whilst DLG1 showed a decrease in both isoforms with increased INSS stage, only the full length L27 containing DLG2 transcripts DLG2-isoform 7/8 showed a decrease in expression in high stage neuroblastoma. We could show that the protein encoded by DLG2-isoform 7 could bind to LIN7A, and increased DLG2-isoform 7 gene expression increased the expression of LIN7A, this reduced neuroblastoma cell proliferation and viability, with increased BAX/BCL2 ratio indicating increased apoptosis. Conclusion: We have provided evidence that gene expression of the L27 domain containing DLG2-isoform 7/8 but not L27 domain lacking DLG2-isoform 2 is disrupted in neuroblastoma, in particular in the aggressive subsets of tumors. The presence of the complete L27 domain allows for the binding to LIN7A, which will control cell polarity and signaling, thus affecting cancer cell viability. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Telomere Maintenance Mechanisms in a Cohort of High-Risk Neuroblastoma Tumors and Its Relation to Genomic Variants in the TERT and ATRX Genes.
- Author
-
Djos, Anna, Thombare, Ketan, Vaid, Roshan, Gaarder, Jennie, Umapathy, Ganesh, Reinsbach, Susanne E., Georgantzi, Kleopatra, Stenman, Jakob, Carén, Helena, Ek, Torben, Mondal, Tanmoy, Kogner, Per, Martinsson, Tommy, and Fransson, Susanne
- Subjects
- *
TELOMERES , *TISSUE arrays , *BIOMARKERS , *NEUROBLASTOMA , *GENE expression , *METHYLATION , *GENOMICS , *RESEARCH funding , *CHILDREN - Abstract
Simple Summary: Immortalization is a hallmark of malignant tumors, including in pediatric cancer neuroblastoma, where it is associated with an adverse prognosis. In this study, we characterized a Swedish neuroblastoma cohort with the focus on telomere maintenance mechanisms (TMMs), i.e., MYCN amplification and the juxtapositioning of TERT and ATRX aberrations. We show a strong correlation between ATRX aberrations and ALT and that aberrations affecting ATRX or TERT are enriched in high-risk cases with 11q deletion. This study, thereby, supports the need for further advancement of TMM-targeted therapies for this subgroup of neuroblastoma patients. Tumor cells are hallmarked by their capacity to undergo unlimited cell divisions, commonly accomplished either by mechanisms that activate TERT or through the alternative lengthening of telomeres pathway. Neuroblastoma is a heterogeneous pediatric cancer, and the aim of this study was to characterize telomere maintenance mechanisms in a high-risk neuroblastoma cohort. All tumor samples were profiled with SNP microarrays and, when material was available, subjected to whole genome sequencing (WGS). Telomere length was estimated from WGS data, samples were assayed for the ALT biomarker c-circles, and selected samples were subjected to methylation array analysis. Samples with ATRX aberration in this study were positive for c-circles, whereas samples with either MYCN amplification or TERT re-arrangement were negative for c-circles. Both ATRX aberrations and TERT re-arrangement were enriched in 11q-deleted samples. An association between older age at diagnosis and 1q-deletion was found in the ALT-positive group. TERT was frequently placed in juxtaposition to a previously established gene in neuroblastoma tumorigenesis or cancer in general. Given the importance of high-risk neuroblastoma, means for mitigating active telomere maintenance must be therapeutically explored. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. Venetoclax in cancer therapy and potential effects on bone.
- Author
-
Zaman, Farasat, Kogner, Per, and Sävendahl, Lars
- Subjects
- *
LYMPHOCYTIC leukemia , *CANCER treatment , *ORAL medicine , *CANCER relapse , *CANCER patients , *CLINICAL trials , *DRUG resistance in cancer cells , *LEUKEMIA treatment - Published
- 2016
- Full Text
- View/download PDF
9. The Swedish childhood tumor biobank: systematic collection and molecular characterization of all pediatric CNS and other solid tumors in Sweden.
- Author
-
Díaz de Ståhl, Teresita, Shamikh, Alia, Mayrhofer, Markus, Juhos, Szilvester, Basmaci, Elisa, Prochazka, Gabriela, Garcia, Maxime, Somarajan, Praveen Raj, Zielinska-Chomej, Katarzyna, Illies, Christopher, Øra, Ingrid, Siesjö, Peter, Sandström, Per-Erik, Stenman, Jakob, Sabel, Magnus, Gustavsson, Bengt, Kogner, Per, Pfeifer, Susan, Ljungman, Gustaf, and Sandgren, Johanna
- Subjects
- *
NUCLEOTIDE sequencing , *CHILD patients , *ONCOLOGISTS , *CENTRAL nervous system , *BRAIN tumors - Abstract
The Swedish Childhood Tumor Biobank (BTB) is a nonprofit national infrastructure for collecting tissue samples and genomic data from pediatric patients diagnosed with central nervous system (CNS) and other solid tumors. The BTB is built on a multidisciplinary network established to provide the scientific community with standardized biospecimens and genomic data, thereby improving knowledge of the biology, treatment and outcome of childhood tumors. As of 2022, over 1100 fresh-frozen tumor samples are available for researchers. We present the workflow of the BTB from sample collection and processing to the generation of genomic data and services offered. To determine the research and clinical utility of the data, we performed bioinformatics analyses on next-generation sequencing (NGS) data obtained from a subset of 82 brain tumors and patient blood-derived DNA combined with methylation profiling to enhance the diagnostic accuracy and identified germline and somatic alterations with potential biological or clinical significance. The BTB procedures for collection, processing, sequencing, and bioinformatics deliver high-quality data. We observed that the findings could impact patient management by confirming or clarifying the diagnosis in 79 of the 82 tumors and detecting known or likely driver mutations in 68 of 79 patients. In addition to revealing known mutations in a broad spectrum of genes implicated in pediatric cancer, we discovered numerous alterations that may represent novel driver events and specific tumor entities. In summary, these examples reveal the power of NGS to identify a wide number of actionable gene alterations. Making the power of NGS available in healthcare is a challenging task requiring the integration of the work of clinical specialists and cancer biologists; this approach requires a dedicated infrastructure, as exemplified here by the BTB. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
10. Multifocal Neuroblastoma and Central Hypoventilation in An Infant with Germline ALK F1174I Mutation.
- Author
-
Djos, Anna, Treis, Diana, Fransson, Susanne, Gordon Murkes, Lena, Wessman, Sandra, Ásmundsson, Jurate, Markström, Agneta, Kogner, Per, and Martinsson, Tommy
- Subjects
- *
HYPOVENTILATION , *NEUROBLASTOMA , *WHOLE genome sequencing , *GERM cells , *AUTONOMIC nervous system , *GENETIC testing - Abstract
A preterm infant with central hypoventilation was diagnosed with multifocal neuroblastoma. Congenital anomalies of the autonomic nervous system in association with neuroblastoma are commonly associated with germline mutations in PHOX2B. Further, the ALK gene is frequently mutated in both familial and sporadic neuroblastoma. Sanger sequencing of ALK and PHOX2B, SNP microarray of three tumor samples and whole genome sequencing of tumor and blood were performed. Genetic testing revealed a germline ALK F1174I mutation that was present in all tumor samples as well as in normal tissue samples from the patient. Neither of the patient's parents presented the ALK variant. Array profiling of the three tumor samples showed that two of them had only numerical aberrations, whereas one sample displayed segmental alterations, including a gain at chromosome 2p, resulting in two copies of the ALK-mutated allele. Whole genome sequencing confirmed the presence of the ALK variant and did not detect any aberrations in the coding or promotor region of PHOX2B. This study is to our knowledge the first to report a de novoALK F1174I germline mutation. This may not only predispose to congenital multifocal neuroblastoma but may also contribute to the respiratory dysfunction seen in this patient. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
11. Amplification of CDK4 and MDM2: a detailed study of a high-risk neuroblastoma subgroup.
- Author
-
Martinez-Monleon, Angela, Kryh Öberg, Hanna, Gaarder, Jennie, Berbegall, Ana P., Javanmardi, Niloufar, Djos, Anna, Ussowicz, Marek, Taschner-Mandl, Sabine, Ambros, Inge M., Øra, Ingrid, Sandstedt, Bengt, Beiske, Klaus, Ladenstein, Ruth, Noguera, Rosa, Ambros, Peter F., Gordon Murkes, Lena, Ljungman, Gustaf, Kogner, Per, Fransson, Susanne, and Martinsson, Tommy
- Subjects
- *
CYCLIN-dependent kinases , *NEUROBLASTOMA , *NEPHROBLASTOMA , *LUNGS , *ABDOMINAL tumors , *BONE marrow - Abstract
In neuroblastoma, MYCN amplification and 11q-deletion are important, although incomplete, markers of high-risk disease. It is therefore relevant to characterize additional alterations that can function as prognostic and/or predictive markers. Using SNP-microarrays, a group of neuroblastoma patients showing amplification of one or multiple 12q loci was identified. Two loci containing CDK4 and MDM2 were commonly co-amplified, although amplification of either locus in the absence of the other was observed. Pharmacological inhibition of CDK4/6 with ribociclib or abemaciclib decreased proliferation in a broad set of neuroblastoma cell lines, including CDK4/MDM2-amplified, whereas MDM2 inhibition by Nutlin-3a was only effective in p53wild-type cells. Combined CDK4/MDM2 targeting had an additive effect in p53wild-type cell lines, while no or negative additive effect was observed in p53mutated cells. Most 12q-amplified primary tumors were of abdominal origin, including those of intrarenal origin initially suspected of being Wilms' tumor. An atypical metastatic pattern was also observed with low degree of bone marrow involvement, favoring other sites such as the lungs. Here we present detailed biological data of an aggressive neuroblastoma subgroup hallmarked by 12q amplification and atypical clinical presentation for which our in vitro studies indicate that CDK4 and/or MDM2 inhibition also could be beneficial. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
12. Genome-wide methylation profiling identifies novel methylated genes in neuroblastoma tumors.
- Author
-
Olsson, Maja, Beck, Stephan, Kogner, Per, Martinsson, Tommy, and Carén, Helena
- Published
- 2016
- Full Text
- View/download PDF
13. TC-hunter: identification of the insertion site of a transgenic gene within the host genome.
- Author
-
Börjesson, Vanja, Martinez-Monleon, Angela, Fransson, Susanne, Kogner, Per, Johnsen, John Inge, Milosevic, Jelena, and López, Marcela Dávila
- Subjects
- *
REGULATOR genes , *TRANSGENIC animals , *TRANSGENIC mice , *DNA sequencing , *GENES - Abstract
Background: Transgenic animal models are crucial for the study of gene function and disease, and are widely utilized in basic biological research, agriculture and pharma industries. Since the current methods for generating transgenic animals result in the random integration of the transgene under study, the phenotype may be compromised due to disruption of known genes or regulatory regions. Unfortunately, most of the tools that predict transgene insertion sites from high-throughput data are not publicly available or not properly maintained. Results: We implemented TC-hunter, Transgene-Construct hunter, an open tool that identifies transgene insertion sites and provides simple reports and visualization aids. It relies on common tools used in the analysis of high-throughput data and makes use of chimeric reads and discordant read pairs to identify and support the transgenic insertion site. To demonstrate its applicability, we applied TC-hunter to four transgenic mice samples harboring the human PPM1D gene, a model used in the study of malignant tumor development. We identified the transgenic insertion site in each sample and experimentally validated them with Touchdown-polymerase chain reaction followed by Sanger sequencing. Conclusions: TC-hunter is an accessible bioinformatics tool that can automatically identify transgene insertion sites from DNA sequencing data with high sensitivity (98%) and precision (92.45%). TC-hunter is a valuable tool that can aid in evaluating any potential phenotypic complications due to the random integration of the transgene and can be accessed at https://github.com/bcfgothenburg/SSF. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
14. Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation.
- Author
-
Treis, Diana, Umapathy, Ganesh, Fransson, Susanne, Guan, Jikui, Mendoza-García, Patricia, Siaw, Joachim T., Wessman, Sandra, Gordon Murkes, Lena, Stenman, Jakob J. E., Djos, Anna, Elfman, Lotta H. M., Johnsen, John Inge, Hallberg, Bengt, Palmer, Ruth H., Martinsson, Tommy, and Kogner, Per
- Subjects
- *
ANAPLASTIC lymphoma kinase , *TROPOMYOSINS , *NEUROBLASTOMA , *GERM cells , *INFANTS , *METASTASIS - Abstract
Personalized molecular workup enabled successful ALK inhibitor treatment in a child with resistant neuroblastoma. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
15. Sustained Response to Entrectinib in an Infant With a Germline ALKAL2 Variant and Refractory Metastatic Neuroblastoma With Chromosomal 2p Gain and Anaplastic Lymphoma Kinase and Tropomyosin Receptor Kinase Activation.
- Author
-
Treis, Diana, Umapathy, Ganesh, Fransson, Susanne, Guan, Jikui, Mendoza-García, Patricia, Siaw, Joachim T., Wessman, Sandra, Gordon Murkes, Lena, Stenman, Jakob J. E., Djos, Anna, Elfman, Lotta H. M., Johnsen, John Inge, Hallberg, Bengt, Palmer, Ruth H., Martinsson, Tommy, and Kogner, Per
- Subjects
- *
ANAPLASTIC lymphoma kinase , *TROPOMYOSINS , *NEUROBLASTOMA , *GERM cells , *INFANTS , *METASTASIS - Abstract
Personalized molecular workup enabled successful ALK inhibitor treatment in a child with resistant neuroblastoma. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
16. Aneuploidy in neuroblastoma tumors is not associated with inactivating point mutations in the STAG2 gene.
- Author
-
Djos, Anna, Fransson, Susanne, Kogner, Per, and Martinsson, Tommy
- Abstract
Background: Chromosomal instability is a hallmark of human cancer caused by errors in mitotic control and chromosome segregation. STAG2 encodes a subunit of the cohesion complex that participates in mitotic chromatid separation and was recently found to show low expression and inactivating mutations in Ewing’s sarcoma, melanoma and glioblastoma. In the childhood tumor neuroblastoma (NB) segmental chromosomal alterations are associated with poor prognosis whereas tumors displaying whole chromosome gains and losses have a much better prognosis. Method: As the genetic contribution to aneuploidy is unknown in NB, we investigated the presence of STAG2 mutations through sequence analysis of all 33 coding exons in 37 primary NB tumors. Results and conclusion: As no STAG2 mutation was detected in this study, we conclude that inactivating mutation of STAG2 is not likely causative to neuroblastoma aneuploidy. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
17. The RASSF gene family members RASSF5, RASSF6 and RASSF7 show frequent DNA methylation in neuroblastoma.
- Author
-
Djos, Anna, Martinsson, Tommy, Kogner, Per, and Carén, Helena
- Subjects
- *
NEUROBLASTOMA , *DNA methylation , *TUMORS in children , *CELL culture , *TUMOR suppressor genes - Abstract
Background: Hypermethylation of promotor CpG islands is a common mechanism that inactivates tumor suppressor genes in cancer. Genes belonging to the RASSF gene family have frequently been reported as epigenetically silenced by promotor methylation in human cancers. Two members of this gene family, RASSF1A and RASSF5A5A have been reported as methylated in neuroblastoma. Data from our previously performed genome-wide DNA methylation array analysis indicated that other members of the RASSF gene family are targeted by DNA methylation in neuroblastoma.Results: In the current study, we found that several of the RASSF family genes (RASSF2, RASSF4, RASSF5, RASSF6,RASSF7, and RASSF10) to various degrees were methylated in neuroblastoma cell lines and primary tumors. In addition, several of the RASSF family genes showed low or absent mRNA expression in neuroblastoma cell lines.RASSF5 and RASSF6 were to various degrees methylated in a large portion of neuroblastoma tumors and RASSF7 was heavily methylated in most tumors. Further, CpG methylation sites in the CpG islands of some RASSF family members could be used to significantly discriminate between biological subgroups of neuroblastoma tumors. For example,RASSF5 methylation highly correlated to MYCN amplification and INRG stage M. Furthermore, high methylation of RASSF6 was correlated to unfavorable outcome, 1p deletion and MYCN amplification in our tumor material.In conclusion: This study shows that several genes belonging to the RASSF gene family are methylated in neuroblastoma. The genes RASSF5, RASSF6 and RASSF7 stand out as the most promising candidate genes for furtherinvestigations in neuroblastoma. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
18. Medulloblastoma.
- Author
-
Baryawno, Ninib, Sveinbjörnsson, Baldur, Kogner, Per, and Johnsen, John Inge
- Published
- 2010
- Full Text
- View/download PDF
19. Omega-3 fatty acids in cancer, the protectors of good and the killers of evil?
- Author
-
Gleissman, Helena, Johnsen, John Inge, and Kogner, Per
- Subjects
- *
OMEGA-3 fatty acids , *CANCER prevention , *CANCER treatment , *CANCER chemotherapy , *CANCER cells , *CELL death , *CELL-mediated cytotoxicity - Abstract
Abstract: Omega-3 fatty acids have been implicated in cancer prevention and treatment. Conventional chemotherapeutics are considered “double-edged swords”, as they kill the cancer cells but also strike the healthy cells causing severe morbidity and sometimes also mortality. Could omega-3 fatty acids in this setting work as a “sword and shield” instead, by being cytotoxic to cancer cells, but at the same time protect healthy cells from these deleterious effects? In addition, may our current diet with decreased omega-3/omega-6 ratio contribute to the increased cancer incidence, and could an omega-3 enriched diet be used as a preventive measure against cancer? Here, we seek answers to these questions by reviewing the effects of omega-3 fatty acids, particularly DHA, on various cancers with emphasis on a cancer of neural origin, neuroblastoma. Results from preventive and therapeutic animal as well as human studies together with mechanisms behind the observed toxicity are summarized. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
20. Soluble factors released by activated cytotoxic T lymphocytes interfere with death receptor pathways in neuroblastoma.
- Author
-
De Geer, Anna, Carlson, Lena-Maria, Kogner, Per, and Levitskaya, Jelena
- Subjects
- *
T cells , *NEUROBLASTOMA , *HLA histocompatibility antigens , *CELL lines , *CELL adhesion , *DIMERS , *CELL death - Abstract
Neuroblastoma (NB) is often described as an unfavorable target for both HLA-restricted and death receptor-mediated elimination by cytotoxic T lymphocytes (CTLs) due to low or absent HLA class I and caspase-8 expression. We investigated the effects of soluble factors released by CTLs activated by TCR triggering (named as activated supernatant; AS) on the levels and composition of cell surface molecules involved in HLA-restricted and HLA-independent NB cell recognition (surface immune phenotype). Using a panel of long-term propagated NB cell lines and freshly isolated primary human NB cells, we analyzed surface expression of the (1) cognate receptors for TNFα, Fas and TRAIL; (2) HLA class I and II heterodimers; (3) adhesion molecules; (4) the intracellular expression and activation of caspase-8, as well as (5) the susceptibility of NB cells to death receptor-mediated killing prior to and after exposure to AS. The exposure of NB cells to soluble factors released by activated CTLs skewed the surface immune phenotype of both long term cultured and primary NB cells, induced the expression and activation of caspase-8 and increased the susceptibility of tumor cells to lysis by TRAIL and Fas-agonistic antibody. Blocking experiments identified IFNγ and TNFα as main factors responsible for modulating the surface antigens of NB cells by AS. Our data suggest that recruitment of CTLs activated on third party targets into the vicinity of the NB tumor mass, may override the “silent” immune phenotype of NB cells via the action of soluble factors. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
21. Whole-genome sequencing of recurrent neuroblastoma reveals somatic mutations that affect key players in cancer progression and telomere maintenance.
- Author
-
Fransson, Susanne, Martinez-Monleon, Angela, Johansson, Mathias, Sjöberg, Rose-Marie, Björklund, Caroline, Ljungman, Gustaf, Ek, Torben, Kogner, Per, and Martinsson, Tommy
- Subjects
- *
NEUROBLASTOMA , *SOMATIC mutation , *TELOMERES , *CANCER invasiveness , *CELLULAR signal transduction - Abstract
Neuroblastoma is the most common and deadly childhood tumor. Relapsed or refractory neuroblastoma has a very poor prognosis despite recent treatment advances. To investigate genomic alterations associated with relapse and therapy resistance, whole-genome sequencing was performed on diagnostic and relapsed lesions together with constitutional DNA from seven children. Sequencing of relapsed tumors indicates somatic alterations in diverse genes, including those involved in RAS-MAPK signaling, promoting cell cycle progression or function in telomere maintenance and immortalization. Among recurrent alterations, CCND1-gain, TERT-rearrangements, and point mutations in POLR2A, CDK5RAP, and MUC16 were shown in ≥ 2 individuals. Our cohort contained examples of converging genomic alterations in primary-relapse tumor pairs, indicating dependencies related to specific genetic lesions. We also detected rare genetic germline variants in DNA repair genes (e.g., BARD1, BRCA2, CHEK2, and WRN) that might cooperate with somatically acquired variants in these patients with highly aggressive recurrent neuroblastoma. Our data indicate the importance of monitoring recurrent neuroblastoma through sequential genomic characterization and that new therapeutic approaches combining the targeting of MAPK signaling, cell cycle progression, and telomere activity are required for this challenging patient group. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
22. Establishment of an in vitro 3D model for neuroblastoma enables preclinical investigation of combined tumor‐stroma drug targeting.
- Author
-
Kock, Anna, Bergqvist, Filip, Steinmetz, Julia, Elfman, Lotta H. M., Korotkova, Marina, Johnsen, John Inge, Jakobsson, Per‐Johan, Kogner, Per, and Larsson, Karin
- Abstract
The majority of anti‐cancer therapies target the proliferating tumor cells, while the tumor stroma, principally unaffected, survives, and provide a niche for surviving tumor cells. Combining tumor cell and stroma‐targeting therapies thus have a potential to improve patient outcome. The neuroblastoma stroma contains cancer‐associated fibroblasts expressing microsomal prostaglandin E synthase‐1 (mPGES‐1). mPGES‐1‐derived prostaglandin E2 (PGE2) is known to promote tumor growth through increased proliferation and survival of tumor cells, immune suppression, angiogenesis, and therapy resistance, and we, therefore, hypothesize that mPGES‐1 constitutes an interesting stromal target. Here, we aimed to develop a relevant in vitro model to study combination therapies. Co‐culturing of neuroblastoma and fibroblast cells in 3D tumor spheroids mimic neuroblastoma tumors with regard to the cyclooxygenase/mPGES‐1/PGE2 pathway. Using the spheroid model, we show that the inhibition of fibroblast‐derived mPGES‐1 enhanced the cytotoxic effect of doxorubicin and vincristine and significantly reduced tumor cell viability and spheroid growth. Cyclic treatment with vincristine in combination with an mPGES‐1 inhibitor abrogated cell repopulation. Moreover, inhibition of mPGES‐1 potentiated the cytotoxic effect of vincristine on established neuroblastoma allografts in mice. In conclusion, we established a 3D neuroblastoma model, highlighting the potential of combining stromal targeting of mPGES‐1 with tumor cell targeting drugs like vincristine. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
23. Whole-body MRI within a surveillance program for carriers with clinically actionable germline TP53 variants - the Swedish constitutional TP53 study SWEP53.
- Author
-
Omran, Meis, Blomqvist, Lennart, Brandberg, Yvonne, Pal, Niklas, Kogner, Per, Ståhlbom, Anne Kinhult, Tham, Emma, and Bajalica-Lagercrantz, Svetlana
- Subjects
- *
BREAST ultrasound , *MEDICAL registries , *HUMAN constitution , *MAGNETIC resonance imaging , *P53 protein , *GENETIC carriers - Abstract
Background: The current guidelines in Sweden regarding individuals with a clinically actionable (i.e. pathogenic or likely pathogenic) germline TP53 variant recommend patients to take part of the national Swedish P53 Study (SWEP53). Methods: The study comprises a patient registry (mandatory for all participants) and three optional parts: a biobank, a surveillance program and a psychosocial evaluation of the surveillance. All known adult eligible carriers regardless of age are offered to take part of the surveillance program offering MRI yearly of the whole-body, breast, and brain as well as breast ultrasound. A special surveillance program is offered for individuals 15–18 years old with a 50% risk of being a mutation carrier or with a verified TP53 variation, includes ultrasound of the abdomen and urine corticosteroid profiles. Clinically motivated further examinations are performed upon need. The national inclusion is performed through the six clinical genetic units in Sweden at Umeå, Uppsala, Stockholm, Gothenburg, Linköping and Lund, and the surveillance is mainly performed through the oncology clinics. Results: To date, a total of 41 adults and 11 children have been included in the study. Conclusions: The SWEP53 is the first structured national surveillance program including radiological and clinical routines for TP53 mutation carriers in the Scandinavian setting. The aim of this publication is to present and describe the ongoing Swedish surveillance study to encourage the initiation of similar studies and to contribute to the knowledge of adequate clinical handling of these cancer prone families. Trial registration: Trial registration number: ISRCTN13103571, retrospectively registered on 14/10/2019. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
24. Chromogranin A and neuron-specific enolase in neuroblastoma: Correlation to stage and prognostic factors.
- Author
-
Georgantzi, Kleopatra, Sköldenberg, Erik G., Stridsberg, Mats, Kogner, Per, Jakobson, Åke, Janson, Eva Tiensuu, and Christofferson, Rolf H. B.
- Subjects
- *
NEUROBLASTOMA , *NEUROENDOCRINE tumors , *IMMUNOTHERAPY , *CHROMOGRANINS , *LEUKEMIA - Abstract
Chromogranin A (CgA) and neuron specific enolase (NSE) are important markers in adult neuroendocrine tumors (NET). Neuroblastoma (NB) has certain neuroendocrine properties. The aim of this study was to correlate blood concentrations of CgA, chromogranin B (CgB), and NSE to prognostic factors and outcome in children with NB. Blood samples from 92 patients with NB, 12 patients with benign ganglioneuroma (GN), 21 patients with non-NB solid tumors, 10 patients with acute leukemias, and 69 healthy children, were analyzed. CgA concentrations were higher in neonates vs. children older than one month in the control group (p < 0.0001), and in neonates with NB vs. the control group (p < 0.01). CgA and NSE concentrations were higher in patients with stages 3 and 4 disease (p < 0.05 and p < 0.05), in patients having tumors with amplification of MYCN (p < 0.05 and p < 0.001), or chromosome 1 p deletion (p < 0.05 and p < 0.05). NSE correlated to the tumor size at diagnosis (p < 0.001) and to tumor related death (p < 0.01) in NB. CgA and NSE concentrations were elevated in patients with NB and especially in those with advanced disease. Both CgA and NSE correlated to genetic markers, while only NSE correlated to primary tumor size and outcome in NB. We found that CgA and NSE are clinically valuable tumor markers in NB and they merit prospective clinical evaluations as such. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
25. Doxorubicin-provoked increase of mitotic activity and concomitant drain of G0-pool in therapy-resistant BE(2)-C neuroblastoma.
- Author
-
Hultman, Isabell, Haeggblom, Linnea, Rognmo, Ingvild, Jansson Edqvist, Josefin, Blomberg, Evelina, Ali, Rouknuddin, Phillips, Lottie, Sandstedt, Bengt, Kogner, Per, Shirazi Fard, Shahrzad, and Ährlund-Richter, Lars
- Subjects
- *
DOXORUBICIN , *NEUROBLASTOMA , *PLURIPOTENT stem cells , *CHILDHOOD cancer , *METASTASIS - Abstract
In this study chemotherapy response in neuroblastoma (NB) was assessed for the first time in a transplantation model comprising non-malignant human embryonic microenvironment of pluripotent stem cell teratoma (PSCT) derived from diploid bona fide hESC. Two NB cell lines with known high-risk phenotypes; the multi-resistant BE(2)-C and the drug sensitive IMR-32, were transplanted to the PSCT model and the tumour growth was exposed to single or repeated treatments with doxorubicin, and thereafter evaluated for cell death, apoptosis, and proliferation. Dose dependent cytotoxic effects were observed, this way corroborating the experimental platform for this type of analysis. Notably, analysis of doxorubicin-resilient BE(2)-C growth in the PSCT model revealed an unexpected 1,5-fold increase in Ki67-index (p<0.05), indicating that non-cycling (G0) cells entered the cell cycle following the doxorubicin exposure. Support for this notion was obtained also in vitro. A pharmacologically relevant dose (1μM) resulted in a marked accumulation of Ki67 positive BE(2)-C cells (p<0.0001), as well as a >3-fold increase in active cell cycle (i.e. cells positive staining for PH3 together with incorporation of EdU) (p<0.01). Considering the clinical challenge for treating high-risk NB, the discovery of a therapy-provoked growth-stimulating effect in the multi-resistant and p53-mutated BE(2)-C cell line, but not in the drug-sensitive p53wt IMR-32 cell line, warrants further studies concerning generality and clinical significance of this new observation. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
26. Rho-associated kinase is a therapeutic target in neuroblastoma.
- Author
-
Dyberg, Cecilia, Fransson, Susanne, Andonova, Teodora, Sveinbjörnsson, Baldur, Lännerholm-Palm, Jessika, Olsen, Thale K., Forsberg, David, Herlenius, Eric, Martinsson, Tommy, Brodin, Bertha, Kogner, Per, Johnsen, John Inge, and Wickström, Malin
- Subjects
- *
NEUROBLASTOMA , *RHO-associated kinases , *SERINE/THREONINE kinases , *GENETIC mutation , *RETINOBLASTOMA - Abstract
Neuroblastoma is a peripheral neural system tumor that originates from the neural crest and is the most common and deadly tumor of infancy. Here we show that neuroblastoma harbors frequent mutations of genes controlling the Rac/Rho signaling cascade important for proper migration and differentiation of neural crest cells during neuritogenesis. RhoA is activated in tumors from neuroblastoma patients, and elevated expression of Rho-associated kinase (ROCK)2 is associated with poor patient survival. Pharmacological or genetic inhibition of ROCK1 and 2, key molecules in Rho signaling, resulted in neuroblastoma cell differentiation and inhibition of neuroblastoma cell growth, migration, and invasion. Molecularly, ROCK inhibition induced glycogen synthase kinase 3β-dependent phosphorylation and degradation ofMYCN protein. Small-molecule inhibition of ROCK suppressed MYCN-driven neuroblastoma growth in TH-MYCN homozygous transgenic mice and MYCN gene-amplified neuroblastoma xenograft growth in nude mice. Interference with Rho/Rac signaling might offer therapeutic perspectives for high-risk neuroblastoma. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
27. Combined epigenetic and differentiation-based treatment inhibits neuroblastoma tumor growth and links HIF2α to tumor suppression.
- Author
-
Westerlund, Isabelle, Yao Shi, Toskas, Konstantinos, Fell, Stuart M., Shuijie Li, Surova, Olga, Södersten, Erik, Kogner, Per, Nyman, Ulrika, Schlisio, Susanne, and Holmberg, Johan
- Subjects
- *
NEUROBLASTOMA , *CHILDHOOD cancer , *CANCER chemotherapy , *DNA methylation , *TUMOR treatment , *PATIENTS - Abstract
Neuroblastoma is a pediatric cancer characterized by variable outcomes ranging from spontaneous regression to life-threatening progression. High-risk neuroblastoma patients receive myeloablative chemotherapy with hematopoietic stem-cell transplant followed by adjuvant retinoid differentiation treatment. However, the overall survival remains low; hence, there is an urgent need for alternative therapeutic approaches. One feature of high-risk neuroblastoma is the high level of DNA methylation of putative tumor suppressors. Combining the reversibility of DNA methylation with the differentiation-promoting activity of retinoic acid (RA) could provide an alternative strategy to treat high-risk neuroblastoma. Here we show that treatment with the DNA-demethylating drug 5-Aza-deoxycytidine (AZA) restores high-risk neuroblastoma sensitivity to RA. Combined systemic distribution of AZA and RA impedes tumor growth and prolongs survival. Genome-wide analysis of treated tumors reveals that this combined treatment rapidly induces a HIF2α-associated hypoxia-like transcriptional response followed by an increase in neuronal gene expression and a decrease in cell-cycle gene expression. A small-molecule inhibitor of HIF2α activity diminishes the tumor response to AZA+RA treatment, indicating that the increase in HIF2α levels is a key component in tumor response to AZA+RA. The link between increased HIF2α levels and inhibited tumor growth is reflected in large neuroblastoma patient datasets. Therein, high levels of HIF2α, but not HIF1α, significantly correlate with expression of neuronal differentiation genes and better prognosis but negatively correlate with key features of high-risk tumors, such as MYCN amplification. Thus, contrary to previous studies, our findings indicate an unanticipated tumor-suppressive role for HIF2α in neuroblastoma. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
28. Neuroblast differentiation during development and in neuroblastoma requires KIF1Bβ-mediated transport of TRKA.
- Author
-
Fell, Stuart M., Shuijie Li, Wallis, Karin, Kock, Anna, Surova, Olga, Rraklli, Vilma, Höfig, Carolin S., Wenyu Li, Mittag, Jens, Henriksson, Marie Arsenian, Kenchappa, Rajappa S., Holmberg, Johan, Kogner, Per, and Schlisio, Susanne
- Subjects
- *
GENETIC mutation , *SYMPATHETIC nervous system , *APOPTOSIS , *LABORATORY mice , *NEUROTROPHINS , *NEUROBLASTOMA - Abstract
We recently identified pathogenic KIF1Bβ mutations in sympathetic nervous systemmalignancies that are defective in developmental apoptosis. Here we deleted KIF1Bβ in the mouse sympathetic nervous system and observed impaired sympathetic nervous function and misexpression of genes required for sympathoadrenal lineage differentiation. We discovered that KIF1Bβ is required for nerve growth factor (NGF)-dependent neuronal differentiation through anterograde transport of the NGF receptor TRKA. Moreover, pathogenic KIF1Bβ mutations identified in neuroblastoma impair TRKA transport. Expression of neuronal differentiation markers is ablated in both KIF1Bβ-deficient mouse neuroblasts and human neuroblastomas that lack KIF1Bβ. Transcriptomic analyses show that unfavorable neuroblastomas resemble mouse sympathetic neuroblasts lacking KIF1Bβ independent of MYCN amplification and the loss of genes neighboring KIF1B on chromosome 1p36. Thus, defective precursor cell differentiation, a common trait of aggressive childhood malignancies, is a pathogenic effect of KIF1Bβ loss in neuroblastomas. Furthermore, neuropathy-associated KIF1Bβ mutations impede cargo transport, providing a direct link between neuroblastomas and neurodegeneration. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
29. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial.
- Author
-
Ladenstein, Ruth, Pötschger, Ulrike, Pearson, Andrew D J, Brock, Penelope, Luksch, Roberto, Castel, Victoria, Yaniv, Isaac, Papadakis, Vassilios, Laureys, Geneviève, Malis, Josef, Balwierz, Walentyna, Ruud, Ellen, Kogner, Per, Schroeder, Henrik, de Lacerda, Ana Forjaz, Beck-Popovic, Maja, Bician, Pavel, Garami, Miklós, Trahair, Toby, and Canete, Adela
- Subjects
- *
BUSULFAN , *MELPHALAN , *CANCER chemotherapy , *GLUCOSIDES , *ANTINEOPLASTIC agents , *IMMUNOSUPPRESSIVE agents , *NEUROBLASTOMA , *CARBOPLATIN , *THERAPEUTICS - Abstract
Summary Background High-dose chemotherapy with haemopoietic stem-cell rescue improves event-free survival in patients with high-risk neuroblastoma; however, which regimen has the greatest patient benefit has not been established. We aimed to assess event-free survival after high-dose chemotherapy with busulfan and melphalan compared with carboplatin, etoposide, and melphalan. Methods We did an international, randomised, multi-arm, open-label, phase 3 cooperative group clinical trial of patients with high-risk neuroblastoma at 128 institutions in 18 countries that included an open-label randomised arm in which high-dose chemotherapy regimens were compared. Patients (age 1–20 years) with neuroblastoma were eligible to be randomly assigned if they had completed a multidrug induction regimen (cisplatin, carboplatin, cyclophosphamide, vincristine, and etoposide with or without topotecan, vincristine, and doxorubicin) and achieved an adequate disease response. Patients were randomly assigned (1:1) to busulfan and melphalan or to carboplatin, etoposide, and melphalan by minimisation, balancing age at diagnosis, stage, MYCN amplification, and national cooperative clinical group between groups. The busulfan and melphalan regimen comprised oral busulfan (150 mg/m 2 given on 4 days consecutively in four equal doses); after Nov 8, 2007, intravenous busulfan was given (0·8–1·2 mg/kg per dose for 16 doses according to patient weight). After 24 h, an intravenous melphalan dose (140 mg/m 2 ) was given. Doses of busulfan and melphalan were modified according to bodyweight. The carboplatin, etoposide, and melphalan regimen consisted of carboplatin continuous infusion of area under the plasma concentration–time curve 4·1 mg/mL per min per day for 4 days, etoposide continuous infusion of 338 mg/m 2 per day for 4 days, and melphalan 70 mg/m 2 per day for 3 days, with doses for all three drugs modified according to bodyweight and glomerular filtration rate. Stem-cell rescue was given after the last dose of high-dose chemotherapy, at least 24 h after melphalan in patients who received busulfan and melphalan and at least 72 h after carboplatin etoposide, and melphalan. All patients received subsequent local radiotherapy to the primary tumour site followed by maintenance therapy. The primary endpoint was 3-year event-free survival, analysed by intention to treat. This trial is registered with ClinicalTrials.gov , number NCT01704716 , and EudraCT, number 2006-001489-17. Findings Between June 24, 2002, and Oct 8, 2010, 1347 patients were enrolled and 676 were eligible for random allocation, 598 (88%) of whom were randomly assigned: 296 to busulfan and melphalan and 302 to carboplatin, etoposide, and melphalan. Median follow-up was 7·2 years (IQR 5·3–9·2). At 3 years, 146 of 296 patients in the busulfan and melphalan group and 188 of 302 in the carboplatin, etoposide, and melphalan group had an event; 3-year event-free survival was 50% (95% CI 45–56) versus 38% (32–43; p=0·0005). Nine patients in the busulfan and melphalan group and 11 in the carboplatin, etoposide, and melphalan group had died without relapse by 5 years. Severe life-threatening toxicities occurred in 13 (4%) patients who received busulfan and melphalan and 29 (10%) who received carboplatin, etoposide, and melphalan. The most frequent grade 3–4 adverse events were general condition (74 [26%] of 281 in the busulfan and melphalan group vs 103 [38%] of 270 in the carboplatin, etoposide, and melphalan group), infection (55 [19%] of 283 vs 74 [27%] of 271), and stomatitis (138 [49%] of 284 vs 162 [59%] of 273); 60 (22%) of 267 patients in the busulfan and melphalan group had Bearman grades 1–3 veno-occlusive disease versus 21 (9%) of 239 in the carboplatin, etoposide, and melphalan group. Interpretation Busulfan and melphalan improved event-free survival in children with high-risk neuroblastoma with an adequate response to induction treatment and caused fewer severe adverse events than did carboplatin, etoposide, and melphalan. Busulfan and melphalan should thus be considered standard high-dose chemotherapy and ongoing randomised studies will continue to aim to optimise treatment for high-risk neuroblastoma. Funding European Commission 5th Framework Grant and the St Anna Kinderkrebsforschung. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
30. The role of formyl peptide receptor 1 (FPR1) in neuroblastoma tumorigenesis.
- Author
-
Snapkov, Igor, Öqvist, Carl Otto, Figenschau, Yngve, Kogner, Per, Johnsen, John Inge, and Sveinbjørnsson, Baldur
- Subjects
- *
FORMYL peptide receptors , *NEOPLASTIC cell transformation , *G protein coupled receptors , *NEUROBLASTOMA , *TUMOR diagnosis , *IMMUNOFLUORESCENCE , *IMMUNOHISTOCHEMISTRY , *LABORATORY mice , *CALCIUM metabolism , *ANIMAL experimentation , *CELL physiology , *CELL receptors , *CELLULAR signal transduction , *CYCLOSPORINE , *GENES , *MICE , *PHOSPHOTRANSFERASES , *PROGNOSIS , *RNA , *TRANSFERASES , *XENOGRAFTS , *PHARMACODYNAMICS - Abstract
Background: Formyl peptide receptor 1 (FPR1) is a G protein-coupled receptor mainly expressed by the cells of myeloid origin, where it mediates the innate immune response to bacterial formylated peptides. High expression of FPR1 has been detected in various cancers but the function of FPR1 in tumorigenesis is poorly understood.Methods: Expression of FPR1 in neuroblastoma cell lines and primary tumors was studied using RT-PCR, western blotting, immunofluorescence and immunohistochemistry. Calcium mobilization assays and western blots with phospho-specific antibodies were used to assess the functional activity of FPR1 in neuroblastoma. The tumorigenic capacity of FPR1 was assessed by xenografting of neuroblastoma cells expressing inducible FPR1 shRNA, FPR1 cDNA or control shRNA in nude mice.Results: FPR1 is expressed in neuroblastoma primary tumors and cell lines. High expression of FPR1 corresponds with high-risk disease and poor patient survival. Stimulation of FPR1 in neuroblastoma cells using fMLP, a selective FPR1 agonist, induced intracellular calcium mobilization and activation of MAPK/Erk, PI3K/Akt and P38-MAPK signal transduction pathways that were inhibited by using Cyclosporin H, a selective receptor antagonist for FPR1. shRNA knock-down of FPR1 in neuroblastoma cells conferred a delayed xenograft tumor development in nude mice, whereas an ectopic overexpression of FPR1 promoted augmented tumorigenesis in nude mice.Conclusion: Our data demonstrate that FPR1 is involved in neuroblastoma development and could represent a therapy option for the treatment of neuroblastoma. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
31. Planar cell polarity gene expression correlates with tumor cell viability and prognostic outcome in neuroblastoma.
- Author
-
Dyberg, Cecilia, Papachristou, Panagiotis, Bjørn Helge Haug, Lagercrantz, Hugo, Kogner, Per, Ringstedt, Thomas, Wickström, Malin, Johnsen, John Inge, and Haug, Bjørn Helge
- Subjects
- *
NEUROBLASTOMA , *GENE expression , *CELL polarity , *CELL survival , *CELL communication , *HEALTH outcome assessment , *PROGNOSIS , *CARCINOGENESIS , *ANIMAL experimentation , *CELL physiology , *CELL motility , *CELLULAR signal transduction , *COMPARATIVE studies , *CYTOSKELETAL proteins , *GENES , *RESEARCH methodology , *MEDICAL cooperation , *MEMBRANE proteins , *MICE , *PHOSPHOTRANSFERASES , *PROTEINS , *RESEARCH , *EVALUATION research , *SIGNAL peptides - Abstract
Background: The non-canonical Wnt/Planar cell polarity (PCP) signaling pathway is a major player in cell migration during embryonal development and has recently been implicated in tumorigenesis.Methods: Transfections with cDNA plasmids or siRNA were used to increase and suppress Prickle1 and Vangl2 expression in neuroblastoma cells and in non-tumorigenic cells. Cell viability was measured by trypan blue exclusion and protein expression was determined with western blotting. Transcriptional activity was studied with luciferase reporter assay and mRNA expression with real-time RT-PCR. Immunofluorescence stainings were used to study the effects of Vangl2 overexpression in non-tumorigenic embryonic cells. Statistical significance was tested with t-test or one-way ANOVA.Results: Here we show that high expression of the PCP core genes Prickle1 and Vangl2 is associated with low-risk neuroblastoma, suppression of neuroblastoma cell growth and decreased Wnt/β-catenin signaling. Inhibition of Rho-associated kinases (ROCKs) that are important in mediating non-canonical Wnt signaling resulted in increased expression of Prickle1 and inhibition of β-catenin activity in neuroblastoma cells. In contrast, overexpression of Vangl2 in MYC immortalized neural stem cells induced accumulation of active β-catenin and decreased the neural differentiation marker Tuj1. Similarly, genetically modified mice with forced overexpression of Vangl2 in nestin-positive cells showed decreased Tuj1 differentiation marker during embryonal development.Conclusions: Our experimental data demonstrate that high expression of Prickle1 and Vangl2 reduce the growth of neuroblastoma cells and indicate different roles of PCP proteins in tumorigenic cells compared to normal cells. These results suggest that the activity of the non-canonical Wnt/PCP signaling pathway is important for neuroblastoma development and that manipulation of the Wnt/PCP pathway provides a possible therapy for neuroblastoma. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
32. The 1p36 Tumor Suppressor KIF 1Bβ Is Required for Calcineurin Activation, Controlling Mitochondrial Fission and Apoptosis.
- Author
-
Li, Shuijie, Fell, Stuart M., Surova, Olga, Smedler, Erik, Wallis, Karin, Chen, Zhi Xiong, Hellman, Ulf, Johnsen, John Inge, Martinsson, Tommy, Kenchappa, Rajappa S., Uhlén, Per, Kogner, Per, and Schlisio, Susanne
- Subjects
- *
CARRIER proteins , *TUMOR suppressor proteins , *CALCINEURIN , *APOPTOSIS , *NEUROBLASTOMA , *MITOCHONDRIAL dynamics , *MITOCHONDRIA , *PROGNOSIS - Abstract
Summary KIF1Bβ is a candidate 1p36 tumor suppressor that regulates apoptosis in the developing sympathetic nervous system. We found that KIF1Bβ activates the Ca 2+ -dependent phosphatase calcineurin (CN) by stabilizing the CN-calmodulin complex, relieving enzymatic autoinhibition and enabling CN substrate recognition. CN is the key mediator of cellular responses to Ca 2+ signals and its deregulation is implicated in cancer, cardiac, neurodegenerative, and immune disease. We show that KIF1Bβ affects mitochondrial dynamics through CN-dependent dephosphorylation of Dynamin-related protein 1 (DRP1), causing mitochondrial fission and apoptosis. Furthermore, KIF1Bβ actuates recognition of all known CN substrates, implying a general mechanism for KIF1Bβ in Ca 2+ signaling and how Ca 2+ -dependent signaling is executed by CN. Pathogenic KIF1Bβ mutations previously identified in neuroblastomas and pheochromocytomas all fail to activate CN or stimulate DRP1 dephosphorylation. Importantly, KIF1Bβ and DRP1 are silenced in 1p36 hemizygous-deleted neuroblastomas, indicating that deregulation of calcineurin and mitochondrial dynamics contributes to high-risk and poor-prognosis neuroblastoma. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
33. Omega-3 fatty acids decrease CRYAB, production of oncogenic prostaglandin E2 and suppress tumor growth in medulloblastoma.
- Author
-
Ljungblad, Linda, Bergqvist, Filip, Tümmler, Conny, Madawala, Samanthi, Olsen, Thale Kristin, Andonova, Teodora, Jakobsson, Per-Johan, Johnsen, John Inge, Pickova, Jana, Strandvik, Birgitta, Kogner, Per, Gleissman, Helena, and Wickström, Malin
- Subjects
- *
OMEGA-3 fatty acids , *TUMOR growth , *MEDULLOBLASTOMA , *EICOSAPENTAENOIC acid , *DOCOSAHEXAENOIC acid , *DINOPROSTONE , *CELL death ,CENTRAL nervous system tumors - Abstract
Medulloblastoma (MB) is one of the most common malignant central nervous system tumors of childhood. Despite intensive treatments that often leads to severe neurological sequelae, the risk for resistant relapses remains significant. In this study we have evaluated the effects of the ω3-long chain polyunsaturated fatty acids (ω3-LCPUFA) docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) on MB cell lines and in a MB xenograft model. Effects of ω3-LCPUFA treatment of MB cells were assessed using the following: WST-1 assay, cell death probes, clonogenic assay, ELISA and western blot. MB cells were implanted into nude mice and the mice were randomized to DHA, or a combination of DHA and EPA treatment, or to control group. Treatment effects in tumor tissues were evaluated with: LC-MS/MS, RNA-sequencing and immunohistochemistry, and tumors, erythrocytes and brain tissues were analyzed with gas chromatography. ω3-LCPUFA decreased prostaglandin E2 (PGE 2) secretion from MB cells, and impaired MB cell viability and colony forming ability and increased apoptosis in a dose-dependent manner. DHA reduced tumor growth in vivo , and both PGE 2 and prostacyclin were significantly decreased in tumor tissue from treated mice compared to control animals. All ω3-LCPUFA and dihomo-γ-linolenic acid increased in tumors from treated mice. RNA-sequencing revealed 10 downregulated genes in common among ω3-LCPUFA treated tumors. CRYAB was the most significantly altered gene and the downregulation was confirmed by immunohistochemistry. Our findings suggest that addition of DHA and EPA to the standard MB treatment regimen might be a novel approach to target inflammation in the tumor microenvironment. [Display omitted] • DHA and EPA impaired cell viability and colony formation of medulloblastoma cells. • ω3-LCPUFA treatment significantly reduced PGE 2 concentration in medulloblastoma. • ω3-LCPUFA treatment deceased expression of CRYAB in medulloblastoma xenografts. • ω3-LCPUFA treatment altered the fatty acid composition in medulloblastoma xenografts. • ω3-LCPUFA offer a novel approach to reduced inflammation and alleviate immune suppression. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
34. Protective Role of Humanin on Bortezomib-Induced Bone Growth Impairment in Anticancer Treatment.
- Author
-
Eriksson, Emma, Wickström, Malin, Perup, Lova Segerström, Johnsen, John I., Eksborg, Staffan, Kogner, Per, and Sävendahl, Lars
- Subjects
- *
BORTEZOMIB , *CHILDHOOD cancer , *GROWTH of children , *BONE growth , *TUMORS in children , *THERAPEUTICS , *CANCER treatment - Abstract
Background Bortezomib is a proteasome inhibitor currently studied in clinical trials of childhood cancers. So far, no side effects on bone growth have been reported in treated children. However, bortezomib was recently found to induce apoptosis in growth plate chondrocytes and impair linear bone growth in treated mice. We hypothesize that [Gly14] humanin (HNG), a 24-amino acid synthetic antiapoptotic peptide, can prevent bortezomib-induced bone growth impairment. Methods Mice with human neuroblastoma or medulloblastoma tumor xenografts (9-13 animals/group) received one 2-week cycle (2 injections/week) of bortezomib (0.8 mg/kg or 1.0 mg/kg), or HNG (1 µg/mouse), or the combination of HNG/bortezomib, or vehicle. Cultures of human growth plate cartilage, chondrogenic- and cancer cell lines, and immunohistochemistry for detection of proapoptotic proteins were also used. Statistical significance was evaluated by two-sided Mann-Whitney U test or by parametric or nonparametric analysis of variance. Results Bortezomib efficiently blocked the proteasome and induced pronounced impairment of linear bone growth from day 0 to day 13 (0.09 mm/day, 95% confidence interval [Cl] = 0.07 to 0.11 mm/day; vs 0.19 mm/day, 95% Cl = 0.15 to 0.23mm/day in vehicle; P< .001), an effect significantly prevented by the addition of HNG (0.15ram growth/day, 95% CI = 0.14 to 0.16mm/day; P< .001 vs bortezomib only; P= 0.03 vs vehicle). Bortezomib was highly toxic when added to cultures of human growth plate cartilage, with markedly increased apoptosis compared with control (P < .001). However, when combining with HNG, bortezomib-induced apoptosis was entirely prevented, as was Bax and PARP activation. Bortezomib delayed tumor growth, and HNG did not interfere with the anticancer effect when studied in human tumor xenografts or cell lines. Conclusions HNG prevents bortezomib-induced bone growth impairment without interfering with bortezomib's desired anti- cancer effects. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
35. ERBB3 is a marker of a ganglioneuroblastoma/ ganglioneuroma-like expression profile in neuroblastic tumours.
- Author
-
Wilzén, Annica, Krona, Cecilia, Sveinbjörnsson, Baldur, Kristiansson, Erik, Dalevi, Daniel, Øra, Ingrid, Preter, Katleen De, Stallings, Raymond L., Maris, John, Versteeg, Rogier, Nilsson, Staffan, Kogner, Per, and Abel, Frida
- Subjects
- *
NEUROBLASTOMA , *NERVOUS system tumors , *GENE expression , *CYTOGENETICS , *IMMUNOHISTOCHEMISTRY - Abstract
Background: Neuroblastoma (NB) tumours are commonly divided into three cytogenetic subgroups. However, by unsupervised principal components analysis of gene expression profiles we recently identified four distinct subgroups, r1-r4. In the current study we characterized these different subgroups in more detail, with a specific focus on the fourth divergent tumour subgroup (r4). Methods: Expression microarray data from four international studies corresponding to 148 neuroblastic tumour cases were subject to division into four expression subgroups using a previously described 6-gene signature. Differentially expressed genes between groups were identified using Significance Analysis of Microarray (SAM). Next, gene expression network modelling was performed to map signalling pathways and cellular processes representing each subgroup. Findings were validated at the protein level by immunohistochemistry and immunoblot analyses. Results: We identified several significantly up-regulated genes in the r4 subgroup of which the tyrosine kinase receptor ERBB3 was most prominent (fold change: 132-240). By gene set enrichment analysis (GSEA) the constructed gene network of ERBB3 (n = 38 network partners) was significantly enriched in the r4 subgroup in all four independent data sets. ERBB3 was also positively correlated to the ErbB family members EGFR and ERBB2 in all data sets, and a concurrent overexpression was seen in the r4 subgroup. Further studies of histopathology categories using a fifth data set of 110 neuroblastic tumours, showed a striking similarity between the expression profile of r4 to ganglioneuroblastoma (GNB) and ganglioneuroma (GN) tumours. In contrast, the NB histopathological subtype was dominated by mitotic regulating genes, characterizing unfavourable NB subgroups in particular. The high ErbB3 expression in GN tumour types was verified at the protein level, and showed mainly expression in the mature ganglion cells. Conclusions: Conclusively, this study demonstrates the importance of performing unsupervised clustering and subtype discovery of data sets prior to analyses to avoid a mixture of tumour subtypes, which may otherwise give distorted results and lead to incorrect conclusions. The current study identifies ERBB3 as a clear-cut marker of a GNB/GN-like expression profile, and we suggest a 7-gene expression signature (including ERBB3) as a complement to histopathology analysis of neuroblastic tumours. Further studies of ErbB3 and other ErbB family members and their role in neuroblastic differentiation and pathogenesis are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
36. PPM1D Is a Therapeutic Target in Childhood Neural Tumors.
- Author
-
Milosevic, Jelena, Treis, Diana, Fransson, Susanne, Gallo-Oller, Gabriel, Sveinbjörnsson, Baldur, Eissler, Nina, Tanino, Keiji, Sakaguchi, Kazuyasu, Martinsson, Tommy, Wickström, Malin, Kogner, Per, and Johnsen, John Inge
- Subjects
- *
BRAIN tumor treatment , *GENETIC mutation , *DNA , *NEUROBLASTOMA , *ONCOGENES , *APOPTOSIS , *GLIOMAS , *GENE expression , *BRAIN tumors , *ESTERASES , *CHILDREN - Abstract
Simple Summary: Medulloblastoma and neuroblastoma are childhood tumors of the central nervous system or the peripheral nervous system, respectively. These are the most common and deadly tumors of childhood. A common genetic feature of medulloblastoma and neuroblastoma is frequent segmental gain or amplification of chromosome 17q. Located on chromosome 17q23.2 is PPM1D which encodes WIP1, a phosphatase that acts as a regulator of p53 and DNA repair. Overexpression of WIP1 correlates with poor patient prognosis. We investigated the effects of genetic or pharmacologic inhibition of WIP1 activity and found that medulloblastoma and neuroblastoma cells were strongly dependent on WIP1 expression for survival. We also tested a number of small molecule inhibitors of WIP1 and show that SL-176 was the most effective compound suppressing the growth of medulloblastoma and neuroblastoma in vitro and in vivo. Childhood medulloblastoma and high-risk neuroblastoma frequently present with segmental gain of chromosome 17q corresponding to aggressive tumors and poor patient prognosis. Located within the 17q-gained chromosomal segments is PPM1D at chromosome 17q23.2. PPM1D encodes a serine/threonine phosphatase, WIP1, that is a negative regulator of p53 activity as well as key proteins involved in cell cycle control, DNA repair and apoptosis. Here, we show that the level of PPM1D expression correlates with chromosome 17q gain in medulloblastoma and neuroblastoma cells, and both medulloblastoma and neuroblastoma cells are highly dependent on PPM1D expression for survival. Comparison of different inhibitors of WIP1 showed that SL-176 was the most potent compound inhibiting medulloblastoma and neuroblastoma growth and had similar or more potent effects on cell survival than the MDM2 inhibitor Nutlin-3 or the p53 activator RITA. SL-176 monotherapy significantly suppressed the growth of established medulloblastoma and neuroblastoma xenografts in nude mice. These results suggest that the development of clinically applicable compounds inhibiting the activity of WIP1 is of importance since PPM1D activating mutations, genetic gain or amplifications and/or overexpression of WIP1 are frequently detected in several different cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
37. High Expression of PPM1D Induces Tumors Phenotypically Similar to TP53 Loss-of-Function Mutations in Mice.
- Author
-
Milosevic, Jelena, Fransson, Susanne, Gulyas, Miklos, Olsen, Thale K., Gallo-Oller, Gabriel, Treis, Diana, Elfman, Lotta H. M., Wilhelm, Margareta, Martinsson, Tommy, Baryawno, Ninib, Kogner, Per, and Johnsen, John Inge
- Subjects
- *
ADENOCARCINOMA , *NEUROBLASTOMA , *ANIMAL experimentation , *PHOSPHATASES , *LEUKEMIA , *NONSENSE mutation , *GENE expression , *GENETIC engineering , *TUMORS , *PHENOTYPES , *MICE , *T-cell lymphoma - Abstract
Simple Summary: Aberrant expression of the PPM1D gene which encodes a phosphatase called WIP1 is frequently observed in cancers of different origins. WIP1 is a negative regulator of the tumor suppressor p53. Improper inactivation of p53 results in genomic instability and can induce neoplastic transformation. We show that overexpression of PPM1D induces tumors in mice similar to cancers harboring p53 mutations. Our results suggest that PPM1D can act as an oncogenic driver by inducing genomic instability, impaired growth arrest, and apoptotic escape that can result in neoplastic transformation and malignant tumor development. PPM1D is a negative regulator of p53 and genomic aberrations resulting in increased activity of PPM1D have been observed in cancers of different origins, indicating that PPM1D has oncogenic properties. We established a transgenic mouse model overexpressing PPM1D and showed that these mice developed a wide variety of cancers. PPM1D-expressing mice developed tumors phenotypically and genetically similar to tumors in mice with dysfunctional p53. T-cell lymphoblastic lymphoma was the most frequent cancer observed in these mice (55%) followed by adenocarcinomas (24%), leukemia (12%) and other solid tumors including neuroblastoma. Characterization of T-cell lymphomas in mice overexpressing PPM1D demonstrates Pten-deletion and p53-accumulation similar to mice with p53 loss-of-function. Also, Notch1 mutations which are recurrently observed in T-cell acute lymphoblastic lymphoma (T-ALL) were frequently detected in PPM1D-transgenic mice. Hence, PPM1D acts as an oncogenic driver in connection with cellular stress, suggesting that the PPM1D gene status and expression levels should be investigated in TP53 wild-type tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
38. MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells.
- Author
-
Zirath, Hanna, Frenzel, Anna, Oliynyk, Ganna, Segerström, Lova, Westermark, Ulrica K., Larsson, Karin, Munksgaard Persson, Matilda, Hultenby, Kjell, Lehtiö, Janne, Einvik, Christer, Påhlmand, Sven, Kogner, Per, Jakobsson, Per-Johan, and Arsenian Henrikssona, Marie
- Subjects
- *
MYC oncogenes , *NEUROBLASTOMA , *CELL cycle , *MITOCHONDRIAL RNA , *CANCER cell differentiation , *LIPID metabolism - Abstract
The MYC genes are the most frequently activated oncogenes in human tumors and are hence attractive therapeutic targets. MYCN amplification leads to poor clinical outcome in childhood neuroblastoma, yet strategies to modulate the function of MYCN do not exist Here we show that 10058-F4, a characterized c-MYC/Max inhibitor, also targets the MYCN/Max interaction, leading to cell cycle arrest, apoptosis, and neuronal differentiation in MYCN-amplified neuroblastoma cells and to increased survival of MYCN transgenic mice. We also report the discovery that inhibition of MYC is accompanied by accumulation of intracellular lipid droplets in tumor cells as a direct consequence of mitochondrial dysfunction. This study expands on the current knowledge of how MYC proteins control the metabolic reprogramming of cancer cells, especially highlighting lipid metabolism and the respiratory chain as important pathways involved in neuroblastoma pathogenesis. Together our data support direct MYC inhibition as a promising strategy for the treatment of MYC-driven tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
39. Age dependence of tumor genetics in unfavorable neuroblastoma: arrayCGH profiles of 34 consecutive cases, using a Swedish 25-year neuroblastoma cohort for validation.
- Author
-
Cetinkaya, Cihan, Martinsson, Tommy, Sandgren, Johanna, Träger, Catarina, Kogner, Per, Dumanski, Jan, de Ståhl, Teresita Díaz, and Hedborg, Fredrik
- Subjects
- *
NEUROBLASTOMA , *CHILDHOOD cancer , *COMBINED modality therapy , *T-test (Statistics) , *TUMORS , *DISEASE progression - Abstract
Background: Aggressive neuroblastoma remains a significant cause of childhood cancer death despite current intensive multimodal treatment protocols. The purpose of the present work was to characterize the genetic and clinical diversity of such tumors by high resolution arrayCGH profiling. Methods: Based on a 32K BAC whole-genome tiling path array and using 50-250K Affymetrix SNP array platforms for verification, DNA copy number profiles were generated for 34 consecutive high-risk or lethal outcome neuroblastomas. In addition, age and MYCN amplification (MNA) status were retrieved for 112 unfavorable neuroblastomas of the Swedish Childhood Cancer Registry, representing a 25-year neuroblastoma cohort of Sweden, here used for validation of the findings. Statistical tests used were: Fisher's exact test, Bayes moderated t-test, independent samples t-test, and correlation analysis. Results: MNA or segmental 11q loss (11q-) was found in 28/34 tumors. With two exceptions, these aberrations were mutually exclusive. Children with MNA tumors were diagnosed at significantly younger ages than those with 11q- tumors (mean: 27.4 vs. 69.5 months; p=0.008; n=14/12), and MNA tumors had significantly fewer segmental chromosomal aberrations (mean: 5.5 vs. 12.0; p<0.001). Furthermore, in the 11q- tumor group a positive correlation was seen between the number of segmental aberrations and the age at diagnosis (Pearson Correlation 0.606; p=0.037). Among nonMNA/non11q- tumors (n=6), one tumor displayed amplicons on 11q and 12q and three others bore evidence of progression from low-risk tumors due to retrospective evidence of disease six years before diagnosis, or due to tumor profiles with high proportions of numerical chromosomal aberrations. An early age at diagnosis of MNA neuroblastomas was verified by registry data, with an average of 29.2 months for 43 cases that were not included in the present study. Conclusion: MNA and segmental 11q loss define two major genetic variants of unfavorable neuroblastoma with apparent differences in their pace of tumor evolution and in genomic integrity. Other possible, but less common, routes in the development of aggressive tumors are progression of low-risk infant-type lesions, and gene amplifications other than MYCN. Knowledge on such nosological diversity of aggressive neuroblastoma might influence future strategies for therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
40. Low-dose aspirin delays an inflammatory tumor progression in vivo in a transgenic mouse model of neuroblastoma.
- Author
-
Carlson, Lena-Maria, Rasmuson, Agnes, Idborg, Helena, Segerström, Lova, Jakobsson, Per-Johan, Sveinbjörnsson, Baldur, and Kogner, Per
- Subjects
- *
DRUG dosage , *ASPIRIN , *INFLAMMATION , *CANCER invasiveness , *TRANSGENIC mice , *NEUROBLASTOMA , *ANIMAL disease models , *DISEASE risk factors - Abstract
Tumor-associated inflammation is a driving force in several adult cancers and intake of low-dose aspirin has proven to reduce cancer incidence. Little is known about tumor-associated inflammation in pediatric neoplasms and no in vivo data exists on the effectiveness of low-dose aspirin on established tumors. The present study employs the transgenic TH-MYCN mouse model for neuroblastoma (NB) to evaluate inflammatory patterns paralleling tumor growth in vivo and low-dose aspirin as a therapeutic option for high-risk NB. Spontaneously arising abdominal tumors were monitored for tumor-associated inflammation ex vivo at various stages of disease and homozygous mice received daily low-dose aspirin (10mg/kg) using oral gavage or no treatment, from 4.5 to 6 weeks of age. Using flow cytometry, a transition from an adaptive immune response predominated by CD8+ T cell in early neoplastic lesions, towards enrichment in immature cells of the innate immune system, including myeloid-derived suppressor cells, dendritic cells and tumor-associated macrophages, was detected during tumor progression. An M1 to M2 transition of tumor-associated macrophages was demonstrated, paralleled by a deterioration of dendritic cell status. Treatment with low-dose aspirin to mice homozygous for the TH-MYCN transgene significantly reduced the tumor burden (P < 0.01), the presence of tumor-associated cells of the innate immune system (P < 0.01), as well as the intratumoral expression of transforming growth factor-β, thromboxane A2 (P < 0.05) and prostaglandin D2 (P < 0.01). In conclusion, tumor-associated inflammation appears as a potential therapeutic target in NB and low-dose aspirin reduces tumor burden in the TH-MYCN transgenic mouse model of NB, hence warranting further studies on aspirin in high-risk NB. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
41. The microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytes.
- Author
-
Carlson, Lena-Maria, De Geer, Anna, Sveinbjørnsson, Baldur, Orrego, Abiel, Martinsson, Tommy, Kogner, Per, and Levitskaya, Jelena
- Subjects
- *
NEUROBLASTOMA , *T cells , *INTERLEUKIN-2 receptors , *PHENOTYPES , *IMMUNOTHERAPY - Abstract
Tumor infiltration by lymphocytes has been linked to improved clinical outcome in children with neuroblastoma (NB) but T-cell activation has never been demonstrated to occur within the NB microenvironment. Here we show that tumor-associated lymphocytes (TALs) obtained from lesions representing all genetic subsets of NB and autologous peripheral blood lymphocytes (PBLs) analyzed on the day of tumor excision differed in composition, phenotype and functional characteristics. The NB microenvironment appeared to promote the accumulation of CD3+CD8+ T cells and contained a larger proportion of T cells expressing the interleukin-2 receptor α chain (CD25) and manifesting an effector memory (CC R7-CD45RA-) phenotype. Accordingly, the stimulation of PBLs with autologous tumor cells in short-term cultures increased the proportion of effector memory T cells, upregulated CD25, stimulated the expression of the TH1 cytokines interferon γ and tumor necrosis factor α, and reduced the expression of transforming growth factor β. In situ proliferation as well as a characteristic pattern of T-cell receptor aggregation at the contact sites with malignant cells was revealed by the immunohistochemical staining of TALs in primary tumors, indicating that the NB milieu is compatible with the activation of the immune system. Our results are compatible with the hypothesis that CD8+ T cells are specifically activated within the NB microenvironment, which appears to be permissive for effector memory responses. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
42. Tumor Development, Growth Characteristics and Spectrum of Genetic Aberrations in the TH-MYCN Mouse Model of Neuroblastoma.
- Author
-
Rasmuson, Agnes, Segerström, Lova, Nethander, Maria, Finnman, Jennie, Elfman, Lotta H. M., Javanmardi, Niloufar, Nilsson, Staffan, Johnsen, John Inge, Martinsson, Tommy, and Kogner, Per
- Subjects
- *
NEUROBLASTOMA , *NEURAL crest , *TUMORS , *NUCLEOTIDE sequence , *CHROMOSOME abnormalities - Abstract
Background: The TH-MYCN transgenic neuroblastoma model, with targeted MYCN expression to the developing neural crest, has been used to study neuroblastoma development and evaluate novel targeted tumor therapies. Methods: We followed tumor development in 395 TH-MYCN (129X1/SvJ) mice (125 negative, 206 hemizygous and 64 homozygous mice) by abdominal palpations up to 40 weeks of age. DNA sequencing of MYCN in the original plasmid construct and mouse genomic DNA was done to verify the accuracy. Copy number analysis with AffymetrixH Mouse Diversity Genotyping Arrays was used to characterize acquired genetic aberrations. Results: DNA sequencing confirmed presence of human MYCN cDNA in genomic TH-MYCN DNA corresponding to the original plasmid construct. Tumor incidence and growth correlated significantly to transgene status with event-free survival for hemizygous mice at 50%, and 0% for homozygous mice. Hemizygous mice developed tumors at 5.6-19 weeks (median 9.1) and homozygous mice at 4.0-6.9 weeks (5.4). The mean treatment window, time from palpable tumor to sacrifice, for hemizygous and homozygous mice was 15 and 5.2 days, respectively. Hemizygous mice developing tumors as early as homozygous mice had a longer treatment window. Age at tumor development did not influence treatment window for hemizygous mice, whereas treatment window in homozygous mice decreased significantly with increasing age. Seven out of 10 analysed tumors had a flat DNA profile with neither segmental nor numerical chromosomal aberrations. Only three tumors from hemizygous mice showed acquired genetic features with one or more numerical aberrations. Of these, one event corresponded to gain on the mouse equivalent of human chromosome 17. Conclusion: Hemizygous and homozygous TH-MYCN mice have significantly different neuroblastoma incidence, tumor growth characteristics and treatment windows but overlap in age at tumor development making correct early genotyping essential to evaluate therapeutic interventions. Contrasting previous studies, our data show that TH-MYCN tumors have few genetic aberrations. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
43. Autocrine Prostaglandin E2 Signaling Promotes Tumor Cell Survival and Proliferation in Childhood Neuroblastoma.
- Author
-
Rasmuson, Agnes, Kock, Anna, Fuskevåg, Ole Martin, Kruspig, Björn, ón-Santamaría, Jaione Sim, Gogvadze, Vladimir, Johnsen, John Inge, Kogner, Per, and ö rnsson, Baldur Sveinbj
- Subjects
- *
PROSTAGLANDINS E , *NEUROBLASTOMA , *TUMORS in children , *MICROBIAL genetics , *MESSENGER RNA , *CYCLIC adenylic acid - Abstract
Background: Prostaglandin E2 (PGE2) is an important mediator in tumor-promoting inflammation. High expression of cyclooxygenase-2 (COX-2) has been detected in the embryonic childhood tumor neuroblastoma, and treatment with COX inhibitors significantly reduces tumor growth. Here, we have investigated the significance of a high COX-2 expression in neuroblastoma by analysis of PGE2 production, the expression pattern and localization of PGE2 receptors and intracellular signal transduction pathways activated by PGE2. Principal Findings: A high expression of the PGE2 receptors, EP1, EP2, EP3 and EP4 in primary neuroblastomas, independent of biological and clinical characteristics, was detected using immunohistochemistry. In addition, mRNA and protein corresponding to each of the receptors were detected in neuroblastoma cell lines. Immunofluorescent staining revealed localization of the receptors to the cellular membrane, in the cytoplasm, and in the nuclear compartment. Neuroblastoma cells produced PGE2 and stimulation of serum-starved neuroblastoma cells with PGE2 increased the intracellular concentration of calcium and cyclic AMP with subsequent phosphorylation of Akt. Addition of 16,16-dimethyl PGE2 (dmPGE2) increased cell viability in a time, dose- and cell line-dependent manner. Treatment of neuroblastoma cells with a COX-2 inhibitor resulted in a diminished cell growth and viability that was reversed by the addition of dmPGE2. Similarly, PGE2 receptor antagonists caused a decrease in neuroblastoma cell viability in a dose-dependent manner. Conclusions: These findings demonstrate that PGE2 acts as an autocrine and/or paracrine survival factor for neuroblastoma cells. Hence, specific targeting of PGE2 signaling provides a novel strategy for the treatment of childhood neuroblastoma through the inhibition of important mediators of tumor-promoting inflammation. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
44. Inhibition of the sonic hedgehog pathway by cyplopamine reduces the CD133+/CD15+ cell compartment and the in vitro tumorigenic capability of neuroblastoma cells
- Author
-
Schiapparelli, Paula, Shahi, Mehdi H., Enguita-Germán, Mónica, Johnsen, John Inge, Kogner, Per, Lázcoz, Paula, and Castresana, Javier S.
- Subjects
- *
NEUROBLASTOMA , *CANCER cells , *AMINES , *GLYCOPROTEINS , *CELL lines , *AUTOCRINE mechanisms , *CELL proliferation , *APOPTOSIS - Abstract
Abstract: Sonic hedgehog (Hh) developmental pathway deregulation has been proven to play an essential role in several malignancies as neuroblastoma. We found that Hh signaling is active in neuroblastoma, as most pathway components, including GLI1, were expressed in cell lines and tumor samples. Furthermore, SHH ligand expression was found in cell lines and tumors, and GLI1 up-regulation was achieved in response to SHH treatment, suggesting an autocrine mechanism of aberrant activation. A decrease of proliferation and tumorigenic potential, as well as increased apoptosis and a dramatic decrease in the percentage of CD15+ cell population were produced upon Hh inhibition by cyclopamine. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
45. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target.
- Author
-
Baryawno, Ninib, Rahbar, Afsar, Wolmer-Solberg, Nina, Taher, Chato, Odeberg, Jenny, Darabi, Anna, Khan, Zahidul, Sveinbjörnsson, Baldur, FuskevÅg, O.-M., Segerström, Lova, Nordenskjöld, Magnus, Siesjö, Peter, Kogner, Per, Johnsen, John Inge, Söderberg-Nauclér, Cecilia, Sveinbjörnsson, Baldur, FuskevÅg, O-M, Segerström, Lova, Nordenskjöld, Magnus, and Siesjö, Peter
- Subjects
- *
CYTOMEGALOVIRUSES , *PROTEINS , *PHOSPHORYLATION , *CELL lines , *DNA , *RNA - Abstract
Medulloblastomas are the most common malignant brain tumors in children. They express high levels of COX-2 and produce PGE2, which stimulates tumor cell proliferation. Human cytomegalovirus (HCMV) is prevalent in the human population and encodes proteins that provide immune evasion strategies and promote oncogenic transformation and oncomodulation. In particular, HCMV induces COX-2 expression; STAT3 phosphorylation; production of PGE2, vascular endothelial growth factor, and IL-6; and tumor formation in vivo. Here, we show that a large proportion of primary medulloblastomas and medulloblastoma cell lines are infected with HCMV and that COX-2 expression, along with PGE2 levels, in tumors is directly modulated by the virus. Our analysis indicated that both HCMV immediate-early proteins and late proteins are expressed in the majority of primary medulloblastomas. Remarkably, all of the human medulloblastoma cell lines that we analyzed contained HCMV DNA and RNA and expressed HCMV proteins at various levels in vitro. When engrafted into immunocompromised mice, human medulloblastoma cells induced expression of HCMV proteins. HCMV and COX-2 expression correlated in primary tumors, cell lines, and medulloblastoma xenografts. The antiviral drug valganciclovir and the specific COX-2 inhibitor celecoxib prevented HCMV replication in vitro and inhibited PGE2 production and reduced medulloblastoma tumor cell growth both in vitro and in vivo. Ganciclovir did not affect the growth of HCMV-negative tumor cell lines. These findings imply an important role for HCMV in medulloblastoma and suggest HCMV as a novel therapeutic target for this tumor. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
46. MYCN-regulated miRNA-92 inhibits secretion of the tumor suppressor DICKKOPF-3 (DKK3) in neuroblastoma.
- Author
-
Haug, Bjørn Helge, Henriksen, Jørn R., Buechner, Jochen, Geerts, Dirk, Tømte, Ellen, Kogner, Per, Martinsson, Tommy, Flægstad, Trond, Sveinbjørnsson, Baldur, and Einvik, Christer
- Subjects
- *
ONCOGENES , *GENETIC regulation , *NON-coding RNA , *TUMOR suppressor proteins , *REGULATION of secretion , *GLYCOPROTEINS , *NEUROBLASTOMA ,TUMOR prognosis - Abstract
The MYCN oncogene is frequently amplified in neuroblastoma. It is one of the most consistent markers of bad prognosis for this disease. Dickkopf-3 (DKK3) is a secreted protein of the DKK family of Wnt regulators. It functions as a tumor suppressor in a range of cancers, including neuroblastoma. MYCN was recently found to downregulate DKK3 mRNA. In this study, we show that MYCN knockdown in MYCN-amplified (MNA) neuroblastoma cell lines increases secretion of endogenous DKK3 to the culture media.MicroRNAs (miRNAs) are ∼20 nt long single-stranded RNA molecules that downregulate messenger RNAs by targeting the 3′ untranslated region (3′UTR). Many miRNAs regulate genes involved in the pathogenesis of cancer and are extensively deregulated in different tumors. Using miRNA target prediction software, we found several MYCN-regulated miRNAs that could target the 3′UTR sequence of DKK3, including mir-92a, mir-92b and let-7e. Luciferase expression from a reporter vector containing the DKK3-3′UTR was decreased when this construct was cotransfected with mir-92a, mir-92b or let-7e in HEK293 cells. Mutation of the mir-92 seed sequence in the 3′UTR completely rescued the observed decrease in reporter expression when cotransfected with mir-92a and mir-92b. Antagomir and miRNA-mimic transfections in neuroblastoma cell lines confirmed that DKK3 secretion to the culture media is regulated by mir-92.Consistent with reports from other cancers, we found DKK3 to be expressed in the endothelium of primary neuroblastoma samples and to be absent in tumors with MYCN amplification.Our data demonstrate that MYCN-regulated miRNAs are able to modulate the expression of the tumor suppressor DKK3 in neuroblastoma. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
47. A 6-gene signature identifies four molecular subgroups of neuroblastoma.
- Author
-
Abel, Frida, Dalevi, Daniel, Nethander, Maria, Jörnsten, Rebecka, De Preter, Katleen, Vermeulen, Joëlle, Stallings, Raymond, Kogner, Per, Maris, John, and Nilsson, Staffan
- Subjects
- *
NERVOUS system tumors , *TUMORS in children , *NEUROBLASTOMA , *PRINCIPAL components analysis , *GENE expression - Abstract
Background: There are currently three postulated genomic subtypes of the childhood tumour neuroblastoma (NB); Type 1, Type 2A, and Type 2B. The most aggressive forms of NB are characterized by amplification of the oncogene MYCN (MNA) and low expression of the favourable marker NTRK1. Recently, mutations or high expression of the familial predisposition gene Anaplastic Lymphoma Kinase (ALK) was associated to unfavourable biology of sporadic NB. Also, various other genes have been linked to NB pathogenesis. Results: The present study explores subgroup discrimination by gene expression profiling using three published microarray studies on NB (47 samples). Four distinct clusters were identified by Principal Components Analysis (PCA) in two separate data sets, which could be verified by an unsupervised hierarchical clustering in a third independent data set (101 NB samples) using a set of 74 discriminative genes. The expression signature of six NB-associated genes ALK, BIRC5, CCND1, MYCN, NTRK1, and PHOX2B, significantly discriminated the four clusters (p < 0.05, one-way ANOVA test). PCA clusters p1, p2, and p3 were found to correspond well to the postulated subtypes 1, 2A, and 2B, respectively. Remarkably, a fourth novel cluster was detected in all three independent data sets. This cluster comprised mainly 11q-deleted MNA-negative tumours with low expression of ALK, BIRC5, and PHOX2B, and was significantly associated with higher tumour stage, poor outcome and poor survival compared to the Type 1-corresponding favourable group (INSS stage 4 and/or dead of disease, p < 0.05, Fisher's exact test). Conclusions: Based on expression profiling we have identified four molecular subgroups of neuroblastoma, which can be distinguished by a 6-gene signature. The fourth subgroup has not been described elsewhere, and efforts are currently made to further investigate this group's specific characteristics. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
48. Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma.
- Author
-
Carén, Helena, Djos, Anna, Nethander, Maria, Sjöberg, Rose-Marie, Kogner, Per, Enström, Camilla, Nilsson, Staffan, and Martinsson, Tommy
- Subjects
- *
GENES , *NEUROBLASTOMA , *DNA methylation , *GENE expression , *HISTONES - Abstract
Background: Epigenetic mechanisms such as DNA methylation and histone modifications are important regulators of gene expression and are frequently involved in silencing tumor suppressor genes. Methods: In order to identify genes that are epigenetically regulated in neuroblastoma tumors, we treated four neuroblastoma cell lines with the demethylating agent 5-Aza-2'-deoxycytidine (5-Aza-dC) either separately or in conjunction with the histone deacetylase inhibitor trichostatin A (TSA). Expression was analyzed using wholegenome expression arrays to identify genes activated by the treatment. These data were then combined with data from genome-wide DNA methylation arrays to identify candidate genes silenced in neuroblastoma due to DNA methylation. Results: We present eight genes (KRT19, PRKCDBP, SCNN1A, POU2F2, TGFBI, COL1A2, DHRS3 and DUSP23) that are methylated in neuroblastoma, most of them not previously reported as such, some of which also distinguish between biological subsets of neuroblastoma tumors. Differential methylation was observed for the genes SCNN1A (p < 0.001), PRKCDBP (p < 0.001) and KRT19 (p < 0.01). Among these, the mRNA expression of KRT19 and PRKCDBP was significantly lower in patients that have died from the disease compared with patients with no evidence of disease (fold change -8.3, p = 0.01 for KRT19 and fold change -2.4, p = 0.04 for PRKCDBP). Conclusions: In our study, a low methylation frequency of SCNN1A, PRKCDBP and KRT19 is significantly associated with favorable outcome in neuroblastoma. It is likely that analysis of specific DNA methylation will be one of several methods in future patient therapy stratification protocols for treatment of childhood neuroblastomas. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
49. High-risk neuroblastoma tumors with 11 q-deletion display a poor prognostic, chromosome instability phenotype with later onset.
- Author
-
Carén, Helena, Kryh, Hanna, Nethander, Maria, Sjöberg, Rose-Marie, Träger, Catarina, Nilsson, Staffan, Abrahamsson, Jonas, Kogner, Per, and Martinsson, Tommy
- Subjects
- *
CHROMOSOME abnormalities , *TUMOR diagnosis , *NEUROBLASTOMA , *CHILDHOOD cancer , *PROGNOSTIC tests - Abstract
Analysis of chromosomal aberrations is used to determine the prognosis of neuroblastomas (NBs) and to aid treatment decisions. MYCN amplification (MNA) alone is an incomplete poor prognostic factor, and chromosome llq status has recently been included in risk classification. We analyzed 165 NB tumors using high-density SNP microarrays and specifically compared the high-risk groups defined by MNA (n = 37) and llq-deletion (n = 21). Median patient age at diagnosis was 21 months for MNA tumors and 42 months for 11 q-deletion tumors, and median survival time after diagnosis was 16 months for MNA and 40 months for 11q deletion. Overall survival (at 8 years) was 35% in both groups. MNA and 1 lq deletion were almost mutually exclusive; only one case harbored both aberrations. The numbers of segmental aberrations differed significantly; the MNA group had a median of four aberrations, whereas the 11 qdeletion group had 12. The high frequency of chromosomal breaks in the 11q-deletion group is suggestive of a chromosomal instability phenotype gene located in 11q; one such gene, H2AFX, is located in 11q23.3 (within the 11q-deletion region). Furthermore, in the groups with segmental aberrations without MNA or llq deletion, the tumors with 17q gain have worse prognosis than those with segmental aberrations without 17q gain, which have a favorable outcome. This study has implications for therapy in different risk groups and stresses that genome-wide microarray analyses should be included in clinical management to fully evaluate risk, aid diagnosis, and guide treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
50. Docosahexaenoic acid metabolome in neural tumors: identification of cytotoxic intermediates.
- Author
-
Gleissman, Helena, Rong Yang, Martinod, Kimberly, Lindskog, Magnus, Serhan, Charles N., Johnsen, John Inge, and Kogner, Per
- Subjects
- *
DOCOSAHEXAENOIC acid , *APOPTOSIS , *NEUROBLASTOMA , *TUMORS , *IMMUNOBLOTTING , *OXIDATION - Abstract
Docosahexaenoic acid (DHA) protects neural cells from stress-induced apoptosis. On the contrary, DHA exerts anticancer effects, and we have shown that DHA induces apoptosis in neuroblastoma, an embryonal tumor of the sympathetic nervous system. We now investigate the DHA metabolome in neuroblastoma using a targeted lipidomic approach in order to elucidate the mechanisms behind the DHA-induced cytotoxicity. LC-MS/MS analysis was used to identify DHA-derived lipid mediators in neuroblastoma cells. Presence of the 15-lipoxygenase enzyme was investigated using immunoblotting, and cytotoxic potency of DHA and DHA-derived compounds was compared using the MTT cell viability assay. Neuroblastoma cells metabolized DHA to 17-hydroxydocosahexaenoic acid (17-HDHA) via 17-hydroperoxydocosahexaenoic acid (17-HpDHA) through 15-lipoxygenase and autoxidation. In contrast to normal neural cells, neuroblastoma cells did not produce the anti-inflammatory and protective lipid mediators, resolvins and protectins. 17-Hp-DHA had significant cytotoxic potency, with an IC50 of 3-6 µM at 72 h, compared to 12-15 µM for DHA. α-Tocopherol protected cells from 17-HpDHA-induced cytotoxicity. DHA inhibited secretion of prostaglandin- E2 and augmented the cytotoxic potency of the cyclooxygenase-2-inhibitor celecoxib. The cytotoxic effect of DHA in neuroblastoma is mediated through production of hydroperoxy fatty acids that accumulate to toxic intracellular levels with restricted production of its products, resolvins and protectins. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.